Literature DB >> 21560267

Abstral (Fentanyl Sublingual Tablets for Breakthrough Cancer Pain).

.   

Abstract

Entities:  

Year:  2011        PMID： 21560267      PMCID： PMC3086091     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  21 in total

1.  A new system for grading recommendations in evidence based guidelines.

Authors:  R Harbour; J Miller
Journal:  BMJ       Date:  2001-08-11

Review 2.  Rational use of sublingual opioids in palliative medicine.

Authors:  Gary M Reisfield; George R Wilson
Journal:  J Palliat Med       Date:  2007-04       Impact factor: 2.947

3.  Management of cancer pain: ESMO clinical recommendations.

Authors:  L Jost; F Roila
Journal:  Ann Oncol       Date:  2008-05       Impact factor: 32.976

4.  Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects.

Authors:  Nicola Lister; Steve Warrington; Malcolm Boyce; Catarina Eriksson; Masami Tamaoka; John Kilborn
Journal:  J Clin Pharmacol       Date:  2011-01-05       Impact factor: 3.126

Review 5.  Assessment and classification of cancer breakthrough pain: a systematic literature review.

Authors:  Dagny Faksvåg Haugen; Marianne Jensen Hjermstad; Neil Hagen; Augusto Caraceni; Stein Kaasa
Journal:  Pain       Date:  2010-03-16       Impact factor: 6.961

6.  Breakthrough pain: definition, prevalence and characteristics.

Authors:  Russell K Portenoy; Neil A Hagen
Journal:  Pain       Date:  1990-06       Impact factor: 6.961

Review 7.  Prevalence of pain in patients with cancer: a systematic review of the past 40 years.

Authors:  M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn
Journal:  Ann Oncol       Date:  2007-03-12       Impact factor: 32.976

8.  In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance.

Authors:  Susanne Bredenberg; Margareta Duberg; Bo Lennernäs; Hans Lennernäs; Anders Pettersson; Marie Westerberg; Christer Nyström
Journal:  Eur J Pharm Sci       Date:  2003-11       Impact factor: 4.384

9.  Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.

Authors:  Richard L Rauck; Marvin Tark; Eva Reyes; Teresa G Hayes; Anthony J Bartkowiak; David Hassman; Srinivas Nalamachu; Rob Derrick; Julian Howell
Journal:  Curr Med Res Opin       Date:  2009-12       Impact factor: 2.580

10.  Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes.

Authors:  H Breivik; N Cherny; B Collett; F de Conno; M Filbet; A J Foubert; R Cohen; L Dow
Journal:  Ann Oncol       Date:  2009-02-24       Impact factor: 32.976
View more
  1 in total

1.  Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.

Authors:  Jordi Guitart; Isabel Vargas; Vicente De Sanctis; Julia Ferreras; Jose Fuentes; Rafael Salazar; Juan M Vázquez; Jordi Folch; Jordi Moya; Hermann Ribera; Francisco Rodelas; Albert Tomás; María Arilla; Joan Coma; Teresa Aberasturi; Dolores Sintes; Ester Lombán
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.